Aquestive Therapeutics (AQST) Stock Price, News, Quotes-Moomoo

US Stock MarketDetailed Quotes

AQST Aquestive Therapeutics

Watchlist

5.150
-0.370-6.70%

Close Nov 4 16:00 ET

5.090
-0.060-1.17%

Post 17:26 ET

468.96MMarket Cap-14305P/E (TTM)

Post-Market

5D
Daily
Weekly
Monthly
1Q
1Y

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

Aquestive Therapeutics Optimistic Financial and Strategic Outlook
TipRanks27minutes ago
Aquestive Therapeutics | 10-Q: Quarterly report
SEC40minutes ago · Announcements
Aquestive Therapeutics: Q3 Earnings Snapshot
Yahoo Finance42minutes ago
Earnings Flash (AQST) AQUESTIVE THERAPEUTICS Posts Q3 Revenue $13.5M
MT Newswires45minutes ago
Aquestive Therapeutics GAAP EPS of -$0.13 In-line, Revenue of $13.54M Beats by $0.86M
Seeking Alpha48minutes ago
Express News | Aquestive Therapeutics Outlook Full-Year Total Revenue $57 Mln to $60 Mln
Reuters53minutes ago

Comments

Good PR re Epi Sublingual med. Good biotech. Huge float

$Aquestive Therapeutics (AQST.US)$

$Aquestive Therapeutics (AQST.US)$
Aquestive Therapeutics Announces Positive Topline Results from Oral Allergy Syndrome (OAS) Challenge Study for Anaphylm™ (epinephrine) Sublingual Film
Aquestive Therapeutics (NASDAQ: AQST) announced positive topline results from its Oral Allergy Syndrome (OAS) challenge study for Anaphylm™ sublingual film. The study met both primary and secondary endpoints, demonstrating rapid symptom resolution beginning two minutes after administration. The median time for...

2

3

$Aquestive Therapeutics (AQST.US)$ Reuters· 1 min ago
Aquestive Therapeutics Inc - Oas Challenge Study Meets Primary and Secondary Endpoints

1

Green Dragon 2024

Increase in shares…

$Aquestive Therapeutics (AQST.US)$

Increase in shares…

Green Dragon 2024

Pfizer monopoly will end…

$Aquestive Therapeutics (AQST.US)$ the monopoly has been going for long enough.

Pfizer monopoly will end…

Read more

Analysis

Analyst Rating

No Data

Price Target

No Data

US

Overall

No Data